Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England

Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England

Summary: Background: Long-term care facilities (LTCFs) have reported high SARS-CoV-2 infection rates and related mortality, but the proportion of infected people among those who have survived, and duration of the antibody response to natural infection, is unknown. We determined the prevalence and s...

Full description

Bibliographic Details
Main Authors: Maria Krutikov, MRCP, Tom Palmer, MSc, Gokhan Tut, PhD, Christopher Fuller, MSc, Borscha Azmi, MSc, Rebecca Giddings, MFPH, Madhumita Shrotri, MFPH, Nayandeep Kaur, MSc, Panagiota Sylla, MSc, Tara Lancaster, PhD, Aidan Irwin-Singer, MA, Andrew Hayward, ProfMD, Paul Moss, ProfPhD, Andrew Copas, ProfPhD, Laura Shallcross, ProfPhD
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:The Lancet. Healthy Longevity
Online Access:http://www.sciencedirect.com/science/article/pii/S2666756821002828

Internet

http://www.sciencedirect.com/science/article/pii/S2666756821002828

Similar Items